TORL BioTherapeutics is focused on advancing innovative antibody-based therapies aimed at transforming the lives of cancer patients. The company is developing a range of therapies, including monoclonal antibodies (mABs) and antibody-drug conjugates (ADCs), targeting novel cancer biomarkers identified through a strategic partnership with the Slamon Research Lab at UCLA. This collaboration enables TORL to leverage cutting-edge research to create a robust pipeline of targeted therapies that address significant unmet medical needs in oncology. Their approach includes utilizing molecular and genetic signatures to ensure that the right therapies are matched with the right patients, supported by companion diagnostics.

The clinical pipeline at TORL BioTherapeutics features multiple active programs targeting various cancer types, including advanced studies on their lead ADC, TORL-1-23, which targets Claudin 6 (CLDN6) in patients with advanced cancer. The company is committed to global clinical development, with a team experienced in bringing impactful cancer treatments to market. Their ongoing clinical trials are designed to evaluate the safety and efficacy of these novel therapies, with a focus on solid tumors and blood cancers, thereby aiming to improve and extend the lives of patients worldwide.

United States

TORL BioTherapeutics is a clinical-stage biopharmaceutical business focused on creating innovative, antibody-based medicines to improve the lives of cancer patients. They are developing a comprehensive pipeline of innovative preclinical ADCs and mAb in oncologic diseases with high unmet medical needs.

TORL BioTherapeutics

Company Details